Claims for Patent: 7,446,090

Summary for Patent: 7,446,090

Title:	FSH formulation
Abstract:	This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
Inventor(s):	Hoffmann; James Arthur (Greenwood, IN), Lu; Jirong (Indianapolis, IN)
Assignee:	Ares Trading S.A. (Aubonne, CH)
Application Number:	11/482,569
Patent Claims:	1. A method for providing a stable, liquid, multi-use human FSH formulation comprising: preparing an aqueous pharmaceutical formulation comprising human FSH and a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof, the human FSH consisting of an .alpha.-subunit having SEQ ID NO:5 and a .beta.-subunit having SEQ ID NO:6 held together by noncovalent interactions, the human FSH being present as the biologically-active, heterodimeric protein form of human FSH at a concentration of about 5.0 .mu.g/mL to about 200 .mu.g/mL, the preservative being present in an amount effective to yield anti-microbial effect for the formulation; and placing the formulation into a vial, the formulation having a stability such that it contains a pharmaceutically-effective mount of FSH after being held in the vial for a period of twenty four hours or greater. 2. The method of claim 1 and which farther includes storing the vial and included formulation at 2-40 degrees C. for a period of time exceeding 2 months, the formulation containing a pharmaceutically-effective amount of FSH after being stored in the vial at 2-40 degrees C. for a period of time exceeding 2 months. 3. The method of claim 1 which comprises placing in the vial an amount of pharmaceutical formulation sufficient for administering to a patient multiple doses of a pharmaceutically-effective amount of human FSH, the formulation in the vial having a stability such that each of the multiple doses inch des a pharmaceutically-effective amount of FSH when administered over a period of twenty four hours or greater. 4. The method of claim 3 in which the amount is sufficient for administering a pharmaceutically-effective amount of human FSH over 96 hours or greater, the formulation in the vial having a stability such that the formulation includes a pharmaceutically-effective amount of FSH for 96 hours or greater. 5. The method of claim 4 in which the amount is sufficient for administering a cycle of treatment to a patient, the formulation in the vial having a stability such that the formulation in eludes a pharmaceutically-effective amount of FSH for administering over a cycle of treatment for a patient. 6. The method of claim 1 which comprises placing the formulation into a pen-injector system, the formulation retaining biological activity after being stored in the pen-injector system at 2-40 degrees C. for a period of time exceeding 2 months. 7. The method of claim 1 in which the preservative is benzyl alcohol. 8. The method of claim 1 in which the preservative is m-cresol. 9. The method of claim 1 in which the formulation has a stability such that the size distribution of the FSH molecules does not change appreciably after 24 hours at 37.degree. C. 10. The method of claim 1 in which the formulation has a stability such that greater than 50% heterodimer remains intact after three months at 37.degree. C. 11. A method for preparing a stable, liquid, reconstituted, multi-use, human FSH formulation comprising: providing a lyophilized mixture of human FSH; providing an aqueous diluent containing a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof; reconstituting the mixture with the diluent such that the resulting formulation contains human FSH consisting of an .alpha.-subunit having SEQ ID NO:5 and a .beta.-subunit having SEQ ID NO:6 held together by noncovalent interactions, the human FSH in the reconstituted mixture being present as the biologically-active, heterodimeric protein form of human FSH at a concentration of about 5.0 .mu.g/mL to about 200 .mu.g/mL, and an effective anti-microbial amount of the preservative, the resulting formulation having a stability such that it contains a pharmaceutically-effective amount of FSH after being held for a period of twenty four hours or greater. 12. The method of claim 11 in which the preservative is benzyl alcohol. 13. The method of claim 11 in which the preservative is m-cresol. 14. The method of claim 11 in which the formulation retains biological activity after being stored in the vial at 2-40 degrees C. for a period of time exceeding 2 months. 15. The method of claim 11 in which the formulation is in an amount sufficient for administering a cycle of treatment to a patient, the formulation having a stability such that the formulation includes a pharmaceutically-effective amount of FSH for administering over a cycle of treatment for a patient. 16. The method of claim 11 and which farther includes holding the resulting formulation for a period of twenty four hours or greater, the formulation containing a pharmaceutically-effective amount of FSH after having been held for twenty four hours or greater. 17. A stable, liquid, multi-use, pharmaceutical formulation, comprising: an aqueous diluent; a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof; and human FSH; said human FSH being present in said pharmaceutical formulation in a solubilized biologically-active heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions; said human FSH being present in the biologically-active, heterodimeric protein form at a concentration of about 5.0 .mu.g/ml to about 200 .mu.g/ml; said preservative being present in said pharmaceutical formulation in an effective anti-microbial amount; the formulation having a Stability such that it contains pharmaceutically-effective amount of FSH after being held for a period of twenty four hours or greater. 18. The pharmaceutical formulation of claim 17, wherein said human FSH present in said pharmaceutical formulation is in sufficient amount to administer multiple instances of an effective dose of the human FSH for ovarian follicle or testicular stimulation in a human. 19. A pharmaceutical product suitable for use in administering human FSH to a patient over a period of twenty four hours or greater, comprising: a single vial containing the pharmaceutical composition of claim 17, wherein said human FSH is present in said single vial in sufficient amount to administer multiple instances of an effective dose of the human FSH for ovarian follicle or testicular stimulation in a human. 20. The pharmaceutical product of claim 19 in which the preservative is benzyl alcohol. 21. The pharmaceutical product of claim 19 in which the preservative is m-cresol. 22. The pharmaceutical product of claim 19 in which the formulation retains biological activity after being stored in the vial at 2-40 degrees C. for a period of time exceeding 2 months. 23. The pharmaceutical product of claim 19 in which the single vial contains an amount of formulation sufficient for administering a cycle of treatment to a patient, the formulation having a stability such that the formulation includes a pharmaceutically-effective amount of FSH for administering over a cycle of treatment for a patient. 24. The pharmaceutical formulation of claim 17 in which the human FSH is recombinant human FSH. 25. The pharmaceutical product of claim 24 in which the preservative is benzyl alcohol. 26. The pharmaceutical product of claim 24 in which the preservative is m-cresol. 27. The pharmaceutical formulation of claim 17 in which the human FSH is substantially pure. 28. The formulation of claim 17 in which the preservative is benzyl alcohol. 29. The formulation of claim 17 in which the preservative is m-cresol. 30. The formulation of claim 17 in which the formulation retains biological activity after being stored in the vial at 2-40 degrees C. for a period of time exceeding 2 months. 31. The formulation of claim 17 in which the formulation is in an amount sufficient for administering a cycle of treatment to a patient, the formulation having a stability such that the formulation includes a pharmaceutically-effective amount of FSH for administering over a cycle of treatment for a patient. 32. A method for providing a stable, liquid, multi-use human FSH formulation comprising: preparing an aqueous pharmaceutical formulation comprising human FSH and a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof, the human FSH consisting of an .alpha.-subunit having SEQ ID NO:5 and a .beta.-subunit having SEQ ID NO:6 held together by noncovalent interactions, the human FSH being present as the biologically-active, heterodimeric protein form of human FSH at a concentration of about 5.0 .mu.g/mL to 2 mg/mL, the preservative being present in an amount effective to yield an anti-microbial effect for the formulation; placing the formulation into a vial; and storing the vial and the included formulation at 2-40 degrees C. for a period of time exceeding 2 months, the formulation included a pharmaceutically-effective amount of FSH after being stored at 2-40 degrees C. for a period of time exceeding 2 months.

Details for Patent 7,446,090

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Organon Usa Llc, A Subsidiary Of Organon & Co.	FOLLISTIM AQ CARTRIDGE	follitropin beta	Injection	021211	March 23, 2004	7,446,090	2018-07-23
Organon Usa Llc, A Subsidiary Of Organon & Co.	FOLLISTIM AQ CARTRIDGE	follitropin beta	Injection	021211	February 11, 2005	7,446,090	2018-07-23

International Patent Family for US Patent 7,446,090

Country	Patent Number	Estimated Expiration
South Africa	200100190
World Intellectual Property Organization (WIPO)	0004913
United States of America	7563763
United States of America	2008051329